GILD News 90.34 07/24/2014 05:12:38 Gilead Sciences (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 90.34 $GILD

Jim Cramer's Top Stock Picks: PEP CELG GILD REGN BIIB CMG
at The Street - 12 mins ago
Cramer says Chipotle is a huge winner while his 'four horsemen' of Celgine, Gilead Sciences, Regeneron and Biogen Idec are pulling away from the biotech pack.

'Fast Money' Recap: Facebook and Analysts' Expectations
at The Street - 1 hr 12 mins ago
The trading panel discussed why they like Facebook's earnings and why they'd avoid Cheesecake Factory.

The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF)
PR Newswire Europe - Wed Jul 23, 11:31PM CDT
MELBOURNE, Australia, July 24, 2014 /PRNewswire/ --

Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries
Business Wire - Wed Jul 23, 11:00PM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead's investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval.

Gilead Stock's Great Expectations and Giant Opportunity
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jul 23, 8:45PM CDT
Today's     earnings report from Gilead Sciences , quite simply, knocked it out of the park.    Analysts were expecting sales of $2.87 billion for Gilead's hepatitis-C treatment blockbuster Sovaldi. The company handily beat...

Gilead Sciences Crushes Second-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Wed Jul 23, 7:30PM CDT
Gilead Sciences reported second-quarter earnings after the bell today, topping consensus for non-GAAP EPS by a noteworthy 31.8% and revenue estimates by 11.4%. Specifically, the company posted  non-GAAP EPS of $2.36 on $6.53 billion in revenue. ...

Jim Cramer's 'Mad Money' Recap: Unconventional Wisdom
at The Street - Wed Jul 23, 7:05PM CDT
Should investors settle for average results? Absolutely not, Cramer says.

Gilead profit more than quadruples on hep C drug
AP - Wed Jul 23, 5:59PM CDT
FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. on Wednesday reported profit that more than quadrupled in its second quarter, topping analysts' expectations on sales of its new breakthrough drug for hepatitis C.

Is Gilead About to Crush Pharmacyclics Stock?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 23, 5:08PM CDT
Pharmacyclics ' and Johnson & Johnson 's Imbruvica may be one loser following the FDA's approval of Gilead 's Zydelig, or so the story went. However, before investors begin abandoning Pharmacyclics shares thinking that Zydelig will...

Final Glance: Biotechnology companies
AP - Wed Jul 23, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:

Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season
at The Street - Wed Jul 23, 4:44PM CDT
In its first two quarters on the market, Sovaldi, a pill used to treat hepatitis C, has delivered $5.8 billion in revenue to Gilead. Remarkable.

How Will Gilead Sciences (GILD) Stock Be Affected By Its Second Quarter Earnings Results?
at The Street - Wed Jul 23, 4:24PM CDT
Gilead Sciences (GILD) beat analysts second quarter earnings estimates by 56 cents per share, posting an EPS of $2.36.

Why Do We Watch the Dow Jones So Closely When its Makeup Makes No Sense?
Alex Planes, The Motley Fool - Motley Fool - Wed Jul 23, 3:30PM CDT
The Dow Jones Industrial Average is a strange beast. With only 30 components, it can't possibly represent the scope of American stock markets as well as the broader S&P 500 . Yet not only does the Dow follow the S&P fairly closely in any...

IPO Stock Watch: Biotechs Are Half Of July Calendar
at Investor's Business Daily - Wed Jul 23, 3:07PM CDT
July could see 19 biotechs go public and currently represent 50% of the 34 IPOs scheduled for the next two weeks, according to Renaissance Capital. It's also a sharp spike from the 38 biotech initial public offerings in the first half of the year....

Gilead Sciences Announces Second Quarter 2014 Financial Results
Business Wire - Wed Jul 23, 3:06PM CDT
--- Sovaldi Sales of $3.48 billion -

FDA approves Gilead Sciences drug for 3 cancers
AP - Wed Jul 23, 2:39PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer.

Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.

3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Jul 23, 1:03PM CDT
I follow a large number of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...

Gilead Sciences (GILD) Approaches New Upside Target of $90.59
Comtex SmarTrend(R) - Wed Jul 23, 12:59PM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $89.27 today and has reached the first level of resistance at $89.96. Analysts will be watching for a cross of the next upside pivot targets of $90.59 and $91.91.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 167

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 125

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 305

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 97

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative DREAM JEANS Enhance Natural Curves with Comfort

Updated Category News Views 194

Stylish Jeans for a Natural Lift In the world of fashion, innovation often leads to surprising breakthroughs that combine style with functionality. One exciting development comes from an inventor who has created a brand-new jean design aimed at enhancing the natural shape of the body. The DREAM JEANS are crafted to provide lift, contour, and shape to the derriere,...

Continue Reading
Swvl Introduces New Contracts and Expands in Saudi Arabia

Updated Category News Views 113

Swvl's New Contracts Signal Growth in Saudi Arabia Swvl Holdings Corp, a leading provider of technology solutions for enterprise and government mobility, has recently made news by finalizing new contracts in Saudi Arabia. These agreements add a remarkable $2.6 million to the company's annual contract value, which accounts for approximately ten percent of Swvl's total...

Continue Reading
Arizona Sonoran Implements New Shareholder Rights Plan

Updated Category News Views 202

Arizona Sonoran Copper Company Announces New Rights Plan Arizona Sonoran Copper Company Inc. (TSX:ASCU | OTCQX:ASCUF) has taken an important step for its shareholders by adopting a new shareholder rights plan effective as of a date in the future. This move is intended to ensure that all shareholders are treated equitably in any future takeover attempts and to guard...

Continue Reading
Champ the Golden Retriever: First Live Mascot of 2026 Games

Updated Category News Views 243

Meet Champ: The Inspiring Live Mascot of the 2026 USA Games As the world prepares for the 2026 Special Olympics USA Games, there's an exciting new addition to the team - Champ, a golden retriever therapy dog. Champ is set to be the first-ever live mascot in the history of these games, embracing the role with an important mission beyond just being a charming face. She is...

Continue Reading
Investors Alert: Important Update on BioAge Labs Safety Issues

Updated Category News Views 147

A Deep Dive into the BioAge Labs Situation Faruqi & Faruqi, LLP is actively assisting investors from BioAge Labs, Inc. (NASDAQ: BIOA) who have experienced losses exceeding $75,000. If you are one of these investors, it is vital to reach out and explore your legal options. Understanding Your Rights Investors who encountered significant losses between critical periods...

Continue Reading